The post Omeros The move came after Omeros announced a licensing and asset purchase agreement with Novo Nordisk. The deal centers on zaltenibart, a MASP-3 inhibitor drug candidate formerly called…
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best stocks to buy under $20. On September 29, Dyne Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare/MHLW granted Orphan…
Tribune Online Researcher develops method for protein-protein structure prediction A Nigerian researcher, Muinat Zubair, has developed a method for predicting protein structure and protein-protein interactions using a combination of experimental…
admin